The prevalence of anti-rubella antibodies in women of childbearing age in Poland

Wysokińska, T; Janaszek, W; Bucholc, B; Górska, Paulina; Gniadek, Grzegorz; J, Slusarczyk; Rawicz, Marcin

doi:10.1016/j.vaccine.2003.11.004

Cited by 20 publications

(16 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our finding was consistent with the results of other studies from Italy, Kenya, Poland, England, and Canada (17,22,(27)(28)(29) but in contrast to other study from Turkey reporting lack of association between these two variables (15).…”

Section: Rubellasupporting

confidence: 93%

Seroprevalence of Rubella Antibodies among Adult Egyptian Females Aged 20-30 Years. Is there a Need for Rubella Vaccination?

Gadallah¹,

Sayed²,

Kandeel³

et al. 2014

Cent Eur J Public Health

View full text Add to dashboard Cite

SUMMARYIntroduction: Egypt adopted a comprehensive strategy to eliminate measles and rubella by conducting a catch up campaign (in 2008) targeting children and young adults in the age group 10-19 years. This study aimed to explore the seroprevalence of rubella among females aged 20 to 30 years in order to provide the Ministry of Health with information to develop future strategies for rubella supplemental immunization activities among women of childbearing age before marriage and conception.Methods: A total of 339 females in the age group 20 to 30 were selected. The study group comprised women who attended the central laboratory of the Ministry of Health for checking up before travelling abroad as pre-travel requirements for visa application. The collected serum samples were tested for rubella-specific IgG antibodies.Results: The overall prevalence of rubella antibodies in the study group was 88.2%. Around 5.0% of females, who reported that they had been vaccinated, were susceptible to rubella. Age, history of measles, mumps and rubella (MMR) vaccination and past history of rubella infection were considered factors associated with seropositivity for rubella.Conclusion: The seroprevalence rate of rubella antibodies among our female study group was considered low.

show abstract

Section: Rubellasupporting

confidence: 93%

Seroprevalence of Rubella Antibodies among Adult Egyptian Females Aged 20-30 Years. Is there a Need for Rubella Vaccination?

Gadallah¹,

Sayed²,

Kandeel³

et al. 2014

Cent Eur J Public Health

View full text Add to dashboard Cite

show abstract

“…Three percent of participating 11 women in the present study appeared to be susceptible to rubella. The data of the 12 present study are comparable to other European countries (Table 3) [17][18][19][20][21][22][23][24][25]. Any 13 effort should be made to reach high immunisation coverage rate with rubella vaccine, 14 since even with high coverage there still are susceptible women.…”

supporting

confidence: 58%

Kinetics of maternal antibodies against rubella and varicella in infants

Leuridan

Hens

Hutse

et al. 2011

Vaccine

View full text Add to dashboard Cite

“…On the other hand, the study showed a null correlation between anti-rubella IgG titres and maternal age. Seroprevalence studies carried out in other countries found positive correlations between the anti-measles IgG titres in neonates/pregnant women and maternal age [14,[28][29][30], and positive [28], negative [31][32][33][34][35] or null [36,37] correlations between the anti-rubella IgG titres in neonates/ pregnant women and maternal age. The present study found the prevalence of protective antirubella IgG titres to be similar in the neonates of autochthonous and immigrant women (96.9 vs. 95.2 %).…”

Section: Discussionmentioning

confidence: 99%

“…However, it is difficult to compare prevalences obtained in different seroprevalence studies due to differences in sampling methods, populations studied and serological tests used. The prevalence of protective antirubella IgG titres found in this study in pregnant women (95 %) was similar to the prevalence found in pregnant women in the United States of America (98 %) [37], Colombia (93 %) [33], Brazil (92 %) [34], Iran (96 %) [30], Turkey (94-100 %) [36,39] and Australia (93 %) [31], while it was higher than the prevalence found in Taiwan (89 %) [40], Germany (87 %) [41], Sudan (72 %) [42] and Poland (89 %) [35]. The prevalence of protective anti-measles titres found in this study in pregnant women (89 %) was similar to the prevalence found in pregnant women or neonates in the United States of America (88 %) [37], Argentina (87 %) [28], Japan (80-90 %) [29] and China (90 %) [43], while it was higher than the prevalence found in Germany (79 %) [41] and Iran (82 %) [30].…”

Section: Discussionmentioning

confidence: 99%

Prevalence of anti-rubella, anti-measles and anti-mumps IgG antibodies in neonates and pregnant women in Catalonia (Spain) in 2013: susceptibility to measles increased from 2003 to 2013

Plans

Ory

Campins

et al. 2015

Eur J Clin Microbiol Infect Dis

View full text Add to dashboard Cite

Non-immune neonates and non-immune pregnant women are at risk of developing rubella, measles and mumps infections, including congenital rubella syndrome. We describe the seroepidemiology of measles, mumps and rubella (MMR) in neonates and pregnant women in Catalonia (Spain). Anti-rubella, anti-measles and anti-mumps serum IgG titres were assessed using enzyme-linked immunosorbent assay (ELISA) tests in 353 cord blood samples from neonates of a representative sample of pregnant women obtained in 2013. The prevalence of protective antibody titres in neonates was 96 % for rubella IgG (≥8 IU/ml), 90 % for measles IgG (>300 IU/ml) and 84 % for mumps IgG (>460 EU/ml). Slightly lower prevalences of protective IgG titres, as estimated from the cord blood titres, were found in pregnant women: 95 % for rubella IgG, 89 % for measles IgG and 81 % for mumps IgG. The anti-measles and anti-mumps IgG titres and the prevalences of protective IgG titres against measles and mumps increased significantly (p < 0.001) with maternal age. The prevalence of protective anti-measles IgG titres decreased by 7 % [odds ratio (OR) = 0.15, p < 0.001), the prevalence of protective anti-rubella IgG titres increased by 3 % (OR = 1.80, p < 0.05) and the MMR vaccination coverage (during childhood) in pregnant women increased by 54 % (OR = 2.09, p < 0.001) from 2003 to 2013. We recommend to develop an MMR prevention programme in women of childbearing age based on mass MMR vaccination or MMR screening and vaccination of susceptible women to increase immunity levels against MMR.

show abstract

The prevalence of anti-rubella antibodies in women of childbearing age in Poland

Cited by 20 publications

References 8 publications

Seroprevalence of Rubella Antibodies among Adult Egyptian Females Aged 20-30 Years. Is there a Need for Rubella Vaccination?

Seroprevalence of Rubella Antibodies among Adult Egyptian Females Aged 20-30 Years. Is there a Need for Rubella Vaccination?

Kinetics of maternal antibodies against rubella and varicella in infants

Prevalence of anti-rubella, anti-measles and anti-mumps IgG antibodies in neonates and pregnant women in Catalonia (Spain) in 2013: susceptibility to measles increased from 2003 to 2013

Contact Info

Product

Resources

About